IL292739B1 - Cognitive medical therapies - Google Patents

Cognitive medical therapies

Info

Publication number
IL292739B1
IL292739B1 IL292739A IL29273922A IL292739B1 IL 292739 B1 IL292739 B1 IL 292739B1 IL 292739 A IL292739 A IL 292739A IL 29273922 A IL29273922 A IL 29273922A IL 292739 B1 IL292739 B1 IL 292739B1
Authority
IL
Israel
Prior art keywords
medicinal
cognitive
treatments
cognitive treatments
medicinal cognitive
Prior art date
Application number
IL292739A
Other languages
English (en)
Hebrew (he)
Other versions
IL292739A (en
Original Assignee
Actinogen Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019903681A external-priority patent/AU2019903681A0/en
Application filed by Actinogen Medical Ltd filed Critical Actinogen Medical Ltd
Publication of IL292739A publication Critical patent/IL292739A/en
Publication of IL292739B1 publication Critical patent/IL292739B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL292739A 2019-09-30 2020-09-30 Cognitive medical therapies IL292739B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2019903681A AU2019903681A0 (en) 2019-09-30 Medicinal cognitive treatments
PCT/AU2020/051043 WO2021062472A1 (en) 2019-09-30 2020-09-30 Medicinal cognitive treatments

Publications (2)

Publication Number Publication Date
IL292739A IL292739A (en) 2022-07-01
IL292739B1 true IL292739B1 (en) 2026-04-01

Family

ID=75336310

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292739A IL292739B1 (en) 2019-09-30 2020-09-30 Cognitive medical therapies

Country Status (10)

Country Link
US (1) US20230000843A1 (https=)
EP (1) EP4037684A4 (https=)
JP (1) JP2022550221A (https=)
KR (1) KR20220080116A (https=)
CN (1) CN114761005A (https=)
CA (1) CA3152902A1 (https=)
CL (1) CL2022000781A1 (https=)
IL (1) IL292739B1 (https=)
MX (1) MX2022003845A (https=)
WO (1) WO2021062472A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202523658A (zh) * 2019-05-24 2025-06-16 美商賽吉醫療公司 化合物、組合物及使用方法
WO2022115620A1 (en) * 2020-11-25 2022-06-02 Sage Therapeutics, Inc. 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
CN120153257A (zh) * 2022-10-07 2025-06-13 射线质医疗有限公司 用于11β-HSD1抑制剂治疗的受试者选择
WO2025073002A1 (en) * 2023-10-03 2025-04-10 Actinogen Medical Limited Tablet formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011135276A1 (en) * 2010-04-29 2011-11-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642621B2 (en) * 2009-09-16 2014-02-04 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011135276A1 (en) * 2010-04-29 2011-11-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
11 P-HYDROXYSTEROID DEHYDROGENASE TYPE 1, BRAIN ATROPHY AND COGNITIVE DECLINE, MACLULLICH, AM. ET AL, 30 January 2012 (2012-01-30) *
ANONIMUS, "XANAMEM™ IN HEALTHY ELDERLY SUBJECTS, 3 February 2019 (2019-02-03) *
CHAPMAN, K. ET AL., 11 P-HYDROXYSTEROID DEHYDROGENASES: INTRACELLULAR GATE-KEEPERS OF TISSUE GLUCOCORTICOID ACTION, 30 July 2013 (2013-07-30) *
SANDEEP, TC. ET AL.,, 11 P-HYDROXYSTEROID DEHYDROGENASE INHIBITION IMPROVES COGNITIVE FUNCTION IN HEALTHY ELDERLY MEN AND TYPE 2 DIABETICS, 27 April 2004 (2004-04-27) *
SELECTION AND EARLY CLINICAL EVALUATION OF THE BRAIN-PENETRANT 11 P-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (1 IP-HSDL) INHIBITOR UE23, WEBSTER, SP., ET AL., 30 March 2017 (2017-03-30) *
SOOY, K. ET AL, COGNITIVE AND DISEASE-MODIFYING EFFECTS OF 11 P-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITION IN MALE TG2576 MICE, A MODEL OF ALZHEIMER'S DISEASE, 31 December 2015 (2015-12-31) *
SOOY, K. ET AL., PARTIAL DEFICIENCY OR SHORT-TERM INHIBITION OF 11 P-HYDROXYSTEROID DEHYDROGENASE TYPE 1 IMPROVES COGNITIVE FUNCTION IN AGING MICE, 13 October 2010 (2010-10-13) *

Also Published As

Publication number Publication date
WO2021062472A1 (en) 2021-04-08
KR20220080116A (ko) 2022-06-14
MX2022003845A (es) 2022-06-22
CN114761005A (zh) 2022-07-15
AU2020359291A1 (en) 2022-04-21
IL292739A (en) 2022-07-01
EP4037684A4 (en) 2023-11-01
CA3152902A1 (en) 2021-04-08
EP4037684A1 (en) 2022-08-10
US20230000843A1 (en) 2023-01-05
JP2022550221A (ja) 2022-11-30
CL2022000781A1 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
SI3947375T1 (sl) Imidazolonilkinolinske spojine in terapevtske uporabe le-teh
GB201900702D0 (en) Therapy
IL292739B1 (en) Cognitive medical therapies
ZA202200731B (en) Combination therapy
GB201914296D0 (en) Treatment
GB201918752D0 (en) New therapy
GB201912365D0 (en) Treatment
GB201912191D0 (en) New therapy
GB201914006D0 (en) Combination Therapy
GB201910473D0 (en) Combination therapy
GB201902579D0 (en) Treatment
GB201906864D0 (en) Combination therapy
AU2019903683A0 (en) Medicinal cognitive treatments
AU2019903681A0 (en) Medicinal cognitive treatments
GB201919036D0 (en) Therapy
GB201912760D0 (en) Treatment
GB201912335D0 (en) Treatment
GB201911816D0 (en) Treatment
GB201916983D0 (en) Therapy
GB201911603D0 (en) Treatment
GB201910755D0 (en) Treatment
GB201914848D0 (en) Therapy
GB201913785D0 (en) Therapy
GB201913797D0 (en) Therapy
GB201912524D0 (en) Therapy